By Editor , 2 October 2026
Amen Clinics Study Finds Postpartum Depression Has Distinct Brain Patterns

Costa Mesa, Calif. – October 02, 2026 -- Nearly 40% of women with postpartum depression showed a hyperfrontal/anterior cingulate cortex brain-activity pattern, more than double the 19.4% rate found in patients with major depression, according to new research from Dr. Daniel Amen and colleagues at Amen Clinics.

By Editor , 25 September 2026
Chonnam Scientists Turn Common Solvent Dichloromethane into Amide Coupling Reagent

Jeollanam-do – September 25, 2026 -- Researchers at Chonnam National University have demonstrated that dichloromethane, a widely used industrial solvent, can directly drive amide bond formation between carboxylic acids and amines, offering manufacturers a cheaper and less hazardous alternative to conventional coupling reagents. The findings, led by Professor Sunwoo Lee of the Department of Chemistry, were published online on July 6, 2026, and appeared in Volume 148, Issue 27 of the Journal of the American Chemical Society on July 15, 2026.

By Editor , 20 September 2026
CU Anschutz Study: Post-Concussion Irritability Tied to PTSD, Pain, Hearing

Aurora, Colo. – September 19, 2026 -- A new study from the University of Colorado Anschutz Marcus Institute for Brain Health finds that irritability following chronic mild traumatic brain injury (mTBI) in military veterans stems from a combination of PTSD symptoms, chronic pain and difficulty understanding speech in noisy environments, not a single psychological cause.

By Editor , 17 September 2026

Singapore – September 16, 2026 -- Researchers at the National University of Singapore (NUS) have eradicated tumours in 75 per cent of tested preclinical models using pulsed electromagnetic fields (PEMFs) alone, without chemotherapy, after just four 30-minute sessions. The study, led by Associate Professor Alfredo Franco-Obregón of the NUS Yong Loo Lin School of Medicine, was published in the journal Smart Medicine on June 4, 2026.

By Editor , 15 September 2026

South San Francisco, Calif. – September 15, 2026 -- Apeximmune Therapeutics said a peer-reviewed study published in Nature independently validates PLA2G2D as a novel immune checkpoint capable of overcoming resistance to anti-PD-1 cancer therapies, with the company's lead antibody AI-306 targeting an IND filing in the second quarter of 2027.